Published online Dec 7, 2019. doi: 10.3748/wjg.v25.i45.6619
Peer-review started: September 5, 2019
First decision: October 14, 2019
Revised: October 29, 2019
Accepted: November 13, 2019
Article in press: November 13, 2019
Published online: December 7, 2019
Processing time: 92 Days and 7.2 Hours
An increasing number of studies have revealed that microRNAs are the main drivers of carcinogenesis including progression to later stages of gastric cancer (GC). Recently, microRNA-760 (miR-760) was identified as a cancer-related miRNA in ovarian cancer and colorectal cancer. Nonetheless, the expression pattern and specific roles of miR-760 in GC have not yet been clarified.
More biomarkers are required for the diagnosis and treatment of GC.
To investigate the expression and molecular mechanism of miR-760 in GC.
MiR-760 expression was analyzed by real-time quantitative polymerase chain reaction in GC tissue and cell lines, and the clinicopathological significance of the miR-760 expression level in GC patients was investigated. Cellular experiments were performed to explore the functions of miR-760 in GC cells. Moreover, the regulatory effects of miR-760/G-protein-coupled receptor kinase interacting protein-1 (GIT1) were investigated using luciferase reporter assay, MTT assay, flow cytometric analysis, and transwell assay. At last, the relationship between the miR-760/GIT1 axis and GC was further confirmed through database analysis.
We found that miR-760 was upregulated in GC tissues and cell lines, and had a significant positive relationship with lymph nodes metastasis and TNM stage. Cellular experiments showed that miR-760 increased the proliferation and invasion capacity of GC cells but promoted apoptosis. Furthermore, miR-760 directly targeted GIT1 and downregulated its expression in GC cells. Moreover, miR-760 increased GIT1 expression to promote GC progression.
Our study demonstrated that the miR-760/GIT1 axis can significantly increase the growth, migration, and invasion of GC cells. This study provides the functional mechanism of new diagnostic biomarkers for GC.
In the future, more in-depth research will be carried out to reveal the important role of miR-760 to enhance the sensitivity of GC detection and to develop novel anti-cancer treatments targeting miR-760 and GIT1. The identification of the miR-760/GIT1 molecular axis may further provide new strategies for GC prevention and treatment.